US/UK/Canada

Share

Pick a time period -
Tags ( Active)

The Annual General Meeting of Kancera AB

The Annual General Meeting of Kancera AB was held in Stockholm on 26 May, 2011. Annual Report and discharge from liabilityThe Company’s Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer were discharged from liability for the shortened financial year 28 April – 31 December, 2010. Election of Board of Directors and Chairman of the Board and compensation to the BoardHåkan Mellstedt, Bernt Magnusson, Anders Essen-Möller, Thomas Olin and Erik Nerpin were re-elected as members of the Board. Anders Åberg had declined re-election.

Flagging message

As of 2 February 2011, Kancera AB's future subsidiary iNovacia AB has sold its entire holding of 864,000 shares in Kancera AB at the price of SEK 7 per share. This means that the Kancera Group will receive around a further SEK 6 million. The divestment of shares entails no dilution. The listing of Kancera's shares on NASDAQ OMX First North is expected to take place in February 2011. The share's short name or ticker is KAN. About Kancera AB (publ) Kancera AB is a biotechnology company which focuses on new and effective drugs for treating leukaemia and solid tumours. For further

Kancera's new share issue oversubscribed

Kancera AB's new share issue to the public ahead of listing on the NASDAQ OMX First North market was oversubscribed. The new share issue comprised 3,600,000 shares. The issue price was SEK 7 per share, which means that Kancera will receive SEK 25.2 million before issue expenses. Thanks to the new share issue, Kancera's share capital will rise to SEK 1,104,000 divided between 13,248,000 shares. The shares subscribed in the offer correspond to 27.2% of the share capital in Kancera. The number of shareholders will rise to approx. 1,600. The listing of Kancera's shares on NASDAQ OMX First

Kancera makes significant progress in pre-clinical drug development against Chronic Leukemia

Kancera AB has discovered compounds that kill Chronic Lymphocytic Leukemia (CLL) 25 times more selectively than cytostatic drugs currently used for treating the disease.“ I have not previously seen a small molecule drug that kill CLL leukemia cells with a precision like the Kancera compound. It is with confidence we now develop a drug that significantly may improve the treatment of patients suffering from the most common chronic leukemia” says Håkan Mellstedt, professor of Oncological biotherapy, Karolinska Institutet and also a founder of Kancera AB. Mellstedt is also a Senior Physician at

Consolidation within Swedish cancer research

Kancera AB (publ) is carrying out a new share issue, will be listed on First North, and is acquiring the research company iNovacia AB – thereby creating an international and highly competitive cancer drug company.Kancera is running two innovative pharmaceutical projects, one targeting leukaemia and one targeting solid tumours. Kancera is also developing new types of cancer models and stem cell techniques which, at a very early stage in the development of a drug candidate – long before clinical studies – make it possible both to demonstrate the actual effect and to show whether the drug

There are no items matching the current filter
There are no more items matching the current filter
Back to top